Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms
Open Access
- 1 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (11), 1683-1693
- https://doi.org/10.1086/587896
Abstract
Background. Telavancin is an investigational, rapidly bactericidal lipoglycopeptide with a multifunctional mechanism of action.This publication has 27 references indexed in Scilit:
- Fifteen-Year Study of the Changing Epidemiology of Methicillin-Resistant Staphylococcus aureusAmerican Journal Of Medicine, 2006
- Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threatThe Lancet, 2006
- Methicillin-ResistantS. aureusInfections among Patients in the Emergency DepartmentThe New England Journal of Medicine, 2006
- Emergence of Community-Acquired Methicillin-Resistant Staphylococcus aureus USA 300 Clone as the Predominant Cause of Skin and Soft-Tissue InfectionsAnnals of Internal Medicine, 2006
- Methicillin-Resistant Staphylococcus aureus: An Evolutionary, Epidemiologic, and Therapeutic OdysseyClinical Infectious Diseases, 2005
- A Clone of Methicillin-ResistantStaphylococcus aureusamong Professional Football PlayersThe New England Journal of Medicine, 2005
- National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004American Journal of Infection Control, 2004
- Epidemiology and Clonality of Community‐Acquired Methicillin‐ResistantStaphylococcus aureusin Minnesota, 1996–1998Clinical Infectious Diseases, 2001
- The Changing Epidemiology of Staphylococcus aureus?Emerging Infectious Diseases, 2001
- Four Pediatric Deaths From Community-Acquired Methicillin-Resistant Staphylococcus aureus--Minnesota and North Dakota, 1997-1999JAMA, 1999